Freedom of Information Request

Reference Number: Ref EPUT.FOI.18.639
Date Received: Date 06/07/2018

*Note to Applicant: As of 1 April 2017, North Essex Partnership University NHS Foundation Trust (NEP) and South Essex Partnership University NHS Foundation Trust (SEPT) merged to form one new organisation known as Essex Partnership University NHS Foundation Trust (EPUT).

Information Requested:

Please see attached document.

Essex Partnership University Hospitals NHS Foundation Trust does not treat these patients and therefore the Trust cannot answer your request.
FOI Request re Non-Small Cell Lung Cancer (NSCLC) Patients

Please provide the following information relating to NSCLC\(^1\) patients treated\(^2\) by your Trust in the 3 months, April 2018 to June 2018 inclusive.

If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.

<table>
<thead>
<tr>
<th>Total number treated Stage IIIB/IV NSCLC Patients</th>
<th>If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:</th>
</tr>
</thead>
</table>
| Patients with NSCLC Stage IIIB/IV (Stage 3b/4)\(^3\) | Total number NSCLC patients
Other (please specify)
Data not held/accessible |

Of the Stage IIIB/IV NSCLC patients, please indicate the number of patients treated by your Trust in the 3 months April 2018 to June 2018 inclusive, with the following therapies.

<table>
<thead>
<tr>
<th>Total number treated Stage IIIB/IV NSCLC Patients</th>
<th>If unable to provide number of stage IIIB/IV NSCLC patients treated, please indicate the level at which data has been provided:</th>
</tr>
</thead>
</table>
| Docetaxel (mono or combination therapy)          | Total number NSCLC patients
Other (please specify)
Data not held/accessible |
| Atezolizumab (Tecentriq)                         | Total number NSCLC patients
Other (please specify)
Data not held/accessible |
| Nivolumab (Opdivo)                               | Total number NSCLC patients
Other (please specify)
Data not held/accessible |
| Pembrolizumab (Keytruda)                         | Total number NSCLC patients
Other (please specify)
Data not held/accessible |

If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred:

---

---

\(^1\) ICD10 C33, C34
\(^2\) Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.
\(^3\) TNM staging for Stage IIIB NSCLC = Any T, N3, M0 or T4, N2, M0; TNM staging for Stage IV NSCLC = Any T, any N, M1
Please include number for both those patients that present at stage III/IV and also those whose cancer has progressed to stage III/IV